When a single dose of replicon was administered 7 days post tumor inoculation, the Ab1c1 mutant IL-2-expressing replicon significantly slowed tumor progression compared to either the ABC IL-2 replicon, the ABC replicon without IL-2, or the vehicle control (Fig. 5d). Here, IL2 is linked to neoplasm.